CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect Period of Adoption, Adjustment	Cumulative Effect Period of Adoption, Adjusted Balance	Common Stock	Common Stock Cumulative Effect Period of Adoption, Adjusted Balance	Retained Earnings	Retained Earnings Cumulative Effect Period of Adoption, Adjustment	Retained Earnings Cumulative Effect Period of Adoption, Adjusted Balance	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Cumulative Effect Period of Adoption, Adjusted Balance
Beginning balance at Dec. 28, 2019	$ 197,751	$ (203)	$ 197,548	$ 9,265	$ 9,265	$ 200,249	$ (203)	$ 200,046	$ (11,763)	$ (11,763)
Beginning balance (in shares) at Dec. 28, 2019				7,814,797	7,814,797
Increase (Decrease) in Shareholders' Equity
Net income	24,507					24,507
Foreign currency translation adjustment	3,280								3,280
Issuance of restricted common stock for contingent consideration	0
Exercise of stock options	2,236			$ 2,236
Exercise of stock options (in shares)				118,841
Share-based compensation expense	3,235			$ 3,235
Restricted shares vesting (in shares)				61,396
Redemption of vested employee restricted shares for tax withholding	(862)			$ (862)
Redemption of vested employee restricted shares for tax withholding (in shares)				(17,695)
Shares repurchased	(13,371)			$ (13,371)
Shares repurchased (in shares)				(283,842)
Accrued dividends on unvested shares	(51)					(51)
Cash dividends paid to shareholders	(7,503)					(7,503)
Ending balance (in shares) at Jan. 02, 2021				7,693,497
Ending balance at Jan. 02, 2021	209,019			$ 503		216,999			(8,483)
Increase (Decrease) in Shareholders' Equity
Net income	41,679					41,679
Foreign currency translation adjustment	(1,467)								(1,467)
Issuance of restricted common stock for contingent consideration	2,250			$ 2,250
Issuance of restricted common stock for contingent consideration (in shares)				40,039
Exercise of stock options	5,157			$ 5,157
Exercise of stock options (in shares)				192,803
Share-based compensation expense	4,086			$ 4,086
Restricted shares vesting (in shares)				65,242
Redemption of vested employee restricted shares for tax withholding	(1,528)			$ (1,528)
Redemption of vested employee restricted shares for tax withholding (in shares)				(20,133)
Shares repurchased	(44,976)			$ (10,468)		(34,508)
Shares repurchased (in shares)				(608,745)
Accrued dividends on unvested shares	(97)					(97)
Cash dividends paid to shareholders	$ (8,289)					(8,289)
Ending balance (in shares) at Jan. 01, 2022	7,362,703			7,362,703
Ending balance at Jan. 01, 2022	$ 205,834			$ 0		215,784			(9,950)
Increase (Decrease) in Shareholders' Equity
Net income	43,619					43,619
Foreign currency translation adjustment	(5,031)								(5,031)
Issuance of restricted common stock for contingent consideration	0
Exercise of stock options	1,411			$ 1,411
Exercise of stock options (in shares)				61,645
Share-based compensation expense	4,773			$ 4,773
Restricted shares vesting (in shares)				66,127
Redemption of vested employee restricted shares for tax withholding	(2,145)			$ (2,145)
Redemption of vested employee restricted shares for tax withholding (in shares)				(21,057)
Shares repurchased	(27,630)			$ (2,296)		(25,334)
Shares repurchased (in shares)				(319,534)
Accrued dividends on unvested shares	(97)					(97)
Cash dividends paid to shareholders	$ (9,580)					(9,580)
Ending balance (in shares) at Dec. 31, 2022	7,149,884			7,149,884
Ending balance at Dec. 31, 2022	$ 211,154			$ 1,743		$ 224,392			$ (14,981)